Show simple item record

dc.contributor.authorHaywood, Alison
dc.contributor.authorDuc, Jacqueline
dc.contributor.authorGood, Phillip
dc.contributor.authorKhan, Sohil
dc.contributor.authorRickett, Kirsty
dc.contributor.authorVayne-Bossert, Petra
dc.contributor.authorHardy, Janet R
dc.date.accessioned2019-07-12T12:30:30Z
dc.date.available2019-07-12T12:30:30Z
dc.date.issued2019
dc.identifier.issn1469-493X
dc.identifier.doi10.1002/14651858.CD012704.pub2
dc.identifier.urihttp://hdl.handle.net/10072/386348
dc.description.abstractBackground: Dyspnoea is a common symptom in advanced cancer, with a prevalence of up to 70% among patients at end of life. The cause of dyspnoea is often multifactorial, and may cause considerable psychological distress and suffering. Dyspnoea is often undertreated and good symptom control is less frequently achieved in people with dyspnoea than in people with other symptoms of advanced cancer, such as pain and nausea. The exact mechanism of action of corticosteroids in managing dyspnoea is unclear, yet corticosteroids are commonly used in palliative care for a variety of non‐specific indications, including pain, nausea, anorexia, fatigue and low mood, despite being associated with a wide range of adverse effects. In view of their widespread use, it is important to seek evidence of the effects of corticosteroids for the management of cancer‐related dyspnoea. Objectives: To assess the effects of systemic corticosteroids for the management of cancer‐related breathlessness (dyspnoea) in adults. Search methods: We searched CENTRAL, MEDLINE, Embase, CINAHL, Science Citation Index Web of Science, Latin America and Caribbean Health Sciences (LILACS) and clinical trial registries, from inception to 25 January 2018. Selection criteria: We included randomised controlled trials that included adults aged 18 years and above. We included participants with cancer‐related dyspnoea when randomised to systemic corticosteroids (at any dose) administered for the relief of cancer‐related dyspnoea or any other indication, compared to placebo, standard or alternative treatment. Data collection and analysis: Five review authors independently assessed trial quality and three extracted data. We used means and standard deviations for each outcome to report the mean difference (MD) with 95% confidence interval (CI). We assessed the risk of bias and quality of evidence using GRADE. We extracted primary outcomes of sensory‐perceptual experience of dyspnoea (intensity of dyspnoea), affective distress (quality of dyspnoea) and symptom impact (burden of dyspnoea or impact on function) and secondary outcomes of serious adverse events, participant satisfaction with treatment and participant withdrawal from trial.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherWILEY
dc.relation.ispartofissue2
dc.relation.ispartofjournalCOCHRANE DATABASE OF SYSTEMATIC REVIEWS
dc.subject.fieldofresearchBiomedical and clinical sciences
dc.subject.fieldofresearchPsychology
dc.subject.fieldofresearchHealth sciences
dc.subject.fieldofresearchcode32
dc.subject.fieldofresearchcode52
dc.subject.fieldofresearchcode42
dc.titleSystemic corticosteroids for the management of cancer-related breathlessness (dyspnoea) in adults
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.hasfulltextNo Full Text
gro.griffith.authorHaywood, Alison
gro.griffith.authorKhan, Sohil A.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record